Low impact
Moderna shares fell nearly 25% intraday and Merck fell 3.7% after trial data on their jointly developed cancer vaccine, combined with Merck's Keytruda, was briefly and prematurely posted on a medical website before being removed ahead of a scheduled ESMO presentation.
Jin1010/23, 12:41 AM
Related assets
Coming up for MRNA
Explore next
Latest MRNA news
Jin1010/23, 05:33 AM
Jin1010/23, 03:02 AM
FirstSquawk08/28, 03:05 AM